Assessment of the presence of cytomegalovirus-neutralizing antibody by a plaque-reduction assay.

Evaluation of the in vitro neutralizing activity of 30 immunoglobulin G (IgG) preparations and seven batches of pooled plasma against human cytomegalovirus (CMV) was performed by plaque-reduction assays. There were definite differences detected by these methods that could permit the selection of preparations with highest titers for clinical trials. The addition of guinea pig complement to the plaque-reduction assay enhanced inhibition of CMV; thus, guinea pig complement should be used in assays of IgG preparations. There was no relationship between the ELISA-derived optical density values of the IgG samples and the titers determined by plaque neutralization. These data suggest that the results of plaque-reduction neutralization assays provide important information about preparations of antibody that may be selected for patient administration. The preparations selected for their high titers by neutralization assays differ significantly from those identified by another method.

[1]  M. Tapper,et al.  Opportunistic Infection Complicating Acquired Immune Deficiency Syndrome: CLINICAL FEATURES OF 25 CASES , 1984, Medicine.

[2]  R. Gale,et al.  Intravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation. Preliminary results of a controlled trial. , 1984, The American journal of medicine.

[3]  R. O'reilly,et al.  Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Randomized trial in bone marrow transplant recipients. , 1984, The American journal of medicine.

[4]  T. Merigan,et al.  Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Levy,et al.  Intracerebral-mass lesions in the acquired immunodeficiency syndrome (AIDS) , 1983, The New England journal of medicine.

[6]  D. Snydman,et al.  Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. , 1983, Annals of internal medicine.

[7]  T. Merigan,et al.  Cytomegalovirus immune plasma in bone marrow transplant recipients. , 1982, Annals of internal medicine.

[8]  R. Betts,et al.  Neutralization and sensitization of cytomegalovirus by IgG antibody, anti‐IgG antibody, and complement , 1982, Journal of medical virology.

[9]  Shanley Jd,et al.  Modification by Adoptive Humoral Immunity of Murine Cytomegalovirus Infection , 1981 .

[10]  H. Balfour,et al.  Cytomegalovirus Disease in Renal Allograft Recipients: A Prospective Study of the Clinical Features, Risk Factors and Impact on Renal Transplantation , 1980, Medicine.

[11]  P. Neiman,et al.  Toxicity and efficacy of human leukocyte interferon for treatment of cytomegalovirus pneumonia after marrow transplantation. , 1980, The Journal of infectious diseases.

[12]  J. Armstrong,et al.  Protective effect of early serum from mice after cytomegalovirus infection , 1978, Infection and immunity.

[13]  P. Neiman,et al.  A prospective analysis interstitial pneumonia and opportunistic viral infection among recipients of allogeneic bone marrow grafts. , 1977, The Journal of infectious diseases.

[14]  R. Buchanan,et al.  Effect of adenine arabinoside on cytomegalovirus infections. , 1974, The Journal of infectious diseases.

[15]  H. Haines,et al.  Complement-requiring neutralizing antibodies in hyperimmune sera to human cytomegaloviruses. , 1971, Journal of immunology.